コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 e setting of nonirradiation RIC regimens for hematologic malignancy.
2 sity conditioning (RIC) transplantations for hematologic malignancy.
3 is laxa is a rare cutaneous manifestation of hematologic malignancy.
4 ilical cord blood (UCB) transplantations for hematologic malignancy.
5 nsplantation (HCT) for therapy of refractory hematologic malignancy.
6 tiple myeloma (MM) is the second most common hematologic malignancy.
7 frailty and its relevance for patients with hematologic malignancy.
8 coccus (VRE) is an important complication of hematologic malignancy.
9 atch) and survival after transplantation for hematologic malignancy.
10 icts the aggressive clinical outcome of this hematologic malignancy.
11 risk of developing AML and CML but no other hematologic malignancies.
12 therapeutically beneficial, particularly for hematologic malignancies.
13 imab vedotin efficacy in other CD30-positive hematologic malignancies.
14 is a promising approach for the treatment of hematologic malignancies.
15 blastic leukemia and lymphoma, but not other hematologic malignancies.
16 therapeutic target for the treatment of non-hematologic malignancies.
17 r cells, have been clinically translated for hematologic malignancies.
18 progression, but is poorly characterized in hematologic malignancies.
19 ribute to the development and progression of hematologic malignancies.
20 ses, 75 %), with 74 % for solid and 26 % for hematologic malignancies.
21 m, which has implications for many solid and hematologic malignancies.
22 nd primary cells obtained from patients with hematologic malignancies.
23 be deregulated by a variety of mechanisms in hematologic malignancies.
24 al therapeutic benefit from blocking PPIs in hematologic malignancies.
25 with a wide variety of cancers, particularly hematologic malignancies.
26 to chemotherapy in human cancers, including hematologic malignancies.
27 Tc1-Th1 antitumor effects against high-risk hematologic malignancies.
28 lure, hepatocellular injury, infections, and hematologic malignancies.
29 therapeutic approaches for cancer, including hematologic malignancies.
30 Twenty-seven patients had underlying hematologic malignancies.
31 tion is increasingly used to treat high-risk hematologic malignancies.
32 (aHSCT) is widely used for the treatment of hematologic malignancies.
33 iation antigens have been developed to treat hematologic malignancies.
34 ent of patients affected by diverse forms of hematologic malignancies.
35 ingly being performed to treat patients with hematologic malignancies.
36 advances have been made in various areas of hematologic malignancies.
37 is commonly employed for hematologic and non-hematologic malignancies.
38 promising clinical agent in the treatment of hematologic malignancies.
39 vent nuclear ABL1-induced apoptosis in these hematologic malignancies.
40 matopoiesis and are frequently implicated in hematologic malignancies.
41 ents to 18 (95% CI, 16-19) for patients with hematologic malignancies.
42 easingly important role in the management of hematologic malignancies.
43 been demonstrated in many cancers, including hematologic malignancies.
44 ions are detected in a substantial number of hematologic malignancies.
45 (CARs) are emerging as powerful therapies in hematologic malignancies.
46 ciated with different survival after BMT for hematologic malignancies.
47 s been used for more than 50 years to combat hematologic malignancies.
48 therapeutic promise in preclinical models of hematologic malignancies.
49 e possible consequences for the treatment of hematologic malignancies.
50 back loop is preclinically effective against hematologic malignancies.
51 groups such as patients with neutropenia and hematologic malignancies.
52 ation (BMT) is used with curative intent for hematologic malignancies.
53 e function and persistence of CAR T cells in hematologic malignancies.
54 cell therapy as a promising approach to all hematologic malignancies.
55 avage (BAL) might be a diagnostic adjunct in hematologic malignancies.
56 ronous cancers, including nonhematologic and hematologic malignancies.
57 % in SOT recipients and 65% in patients with hematologic malignancies.
58 system to treat a variety of both solid and hematologic malignancies.
59 eased significantly over time, especially in hematologic malignancies.
60 thogenesis and progression of both solid and hematologic malignancies.
61 ng patient survival both in solid tumors and hematologic malignancies.
62 mes across numerous types of solid tumor and hematologic malignancies.
63 les, which contribute to the pathogenesis of hematologic malignancies.
64 cohort study of critically ill patients with hematologic malignancies.
65 ein and is observed in patients with diverse hematologic malignancies.
66 targeted PI3K inhibitors in the treatment of hematologic malignancies.
67 hematopoietic stem cell transplantation for hematologic malignancies.
68 in HIV-1-infected individuals with high-risk hematologic malignancies.
69 might be an attractive new approach to treat hematologic malignancies.
70 xploring CD4+ T cell-based immunotherapy for hematologic malignancies.
71 nsplantation is used as curative therapy for hematologic malignancies.
72 s a novel 2-pronged therapeutic strategy for hematologic malignancies.
73 may disproportionately affect patients with hematologic malignancies.
74 d mortality, seen primarily in patients with hematologic malignancies.
75 ranslocations are a genomic hallmark of many hematologic malignancies.
76 ad >/=30.0 x 10(9) leukocytes/microL without hematologic malignancies.
77 ociated with a higher risk of early death in hematologic malignancies.
78 ved HBV infection receiving chemotherapy for hematologic malignancies.
79 ly produce positive results in patients with hematologic malignancies.
80 y of duvelisib in 210 patients with advanced hematologic malignancies.
81 drug response in 86 patients with refractory hematologic malignancies.
82 nce, survival, and outcomes in patients with hematologic malignancies.
83 tification of novel treatment strategies for hematologic malignancies.
84 in personalized management of patients with hematologic malignancies.
85 own about these disparities in patients with hematologic malignancies.
86 linical relevance of CH in patients with non-hematologic malignancies.
87 actors have emerged as a hallmark of several hematologic malignancies.
88 Some are associated with predisposition to hematologic malignancies.
89 hich -DNMT3A- is frequently mutated in human hematologic malignancies.
90 f malignancies arising in donors including 3 hematologic malignancies.
91 or in combination, in both solid tumors and hematologic malignancies.
92 ay increase treatment options for aggressive hematologic malignancies.
93 s among the most frequently mutated genes in hematologic malignancies.
94 ection afflicting patients with diabetes and hematologic malignancies.
95 e measures are appropriate for patients with hematologic malignancies.
96 tumors, and similar evidence has emerged in hematologic malignancies.
97 n important role in detection and staging of hematologic malignancies.
98 omised, distributed into solid tumors (122), hematologic malignancies (106), and nonmalignant immunos
99 Mortality for admissions with underlying hematologic malignancy (22.7%) was similar to that of ad
101 plantation (CBT) is an effective therapy for hematologic malignancies, acute graft-versus-host diseas
102 methyltransferase 3A (DNMT3A) is mutated in hematologic malignancies affecting myeloid, mixed, and l
103 22 primary patient samples from a variety of hematologic malignancies against a panel of 48 drug comb
104 s performed of 271 consecutive patients with hematologic malignancies, age 50 to 75 years, who receiv
105 among parents and providers of patients with hematologic malignancies, although there were no differe
106 ) patients, including 18 (36%) patients with hematologic malignancies and 5 (10%) patients with solid
108 bispecific antibodies (bsAb) show promise in hematologic malignancies and are also being evaluated in
109 ex combs-like 1 (ASXL1) are found in various hematologic malignancies and associated with poor progno
110 and systemic diseases such as B-cell lineage hematologic malignancies and connective tissue disorders
111 hereditary cancer syndromes with associated hematologic malignancies and contribute to clinically ef
112 en found in a variety of solid tumors and in hematologic malignancies and has been correlated with po
113 d higher rates of spontaneous tumors, mainly hematologic malignancies and hepatocellular adenomas and
114 In patients with MPN, the HRs of death from hematologic malignancies and infections were 92.8 (95% C
116 activation-dampening molecule participate in hematologic malignancies and may serve as a key determin
118 and tumor models, representing a variety of hematologic malignancies and solid tumor indications.
119 erapy not only of lymphoma but also in other hematologic malignancies and solid tumors that do not ev
121 ch can impact outcome through progression to hematologic malignancies and through cell-non-autonomous
122 ients age 70 years or older who had solid or hematologic malignancies and underwent a geriatric asses
127 ve been made with DNA-demethylating drugs in hematologic malignancies, and efforts are underway to ta
129 the increased risks for autoimmune diseases, hematologic malignancies, and respiratory tract infectio
130 fied T cells, describe the extant results in hematologic malignancies, and share our outlook on where
136 individuals with germ line predisposition to hematologic malignancies are diagnosed with increasing f
139 emained limited and lagged behind many other hematologic malignancies because of the inherent difficu
140 ) signaling and are used in the treatment of hematologic malignancies, block BCR-mediated lytic induc
141 d to investigate the effectiveness of ICs in hematologic malignancies both as monotherapy and in mult
142 tor that is currently in clinical trials for hematologic malignancies, both ex vivo and in xenotransp
143 ctivation is most common during treatment of hematologic malignancies but also occurs with chemothera
144 rty-seven individuals had breast cancer or a hematologic malignancy but had not yet initiated their t
145 een successfully applied to the treatment of hematologic malignancies, but faces many challenges in s
146 allogeneic hematopoietic stem cells to cure hematologic malignancies, but the basis for this synergy
147 main in the field of CAR T cells directed to hematologic malignancies, but the encouraging response r
148 plant (allo-HCT) can be curative for certain hematologic malignancies, but the risk of graft-versus-h
149 ave mediated dramatic antitumor responses in hematologic malignancies, but tumor regression has rarel
151 hat should help to advance drug discovery in hematologic malignancies by successful targeting of new
153 extracranial embryonal tumors, brain tumors, hematologic malignancies, carcinomas, and gonadal tumors
154 Primary myelofibrosis (PMF) is a clonal hematologic malignancy characterized by BM fibrosis, ext
156 Acute myeloid leukemia (AML) is a deadly hematologic malignancy characterized by the uncontrolled
157 from the IARC added details for prostate and hematologic malignancies, classifying the evidence as su
158 atients with reactive monocytosis or another hematologic malignancy, CMML patients demonstrate a char
160 ndritic cell neoplasm (BPDCN), an aggressive hematologic malignancy derived from plasmacytoid dendrit
165 starting dose of lenalidomide used in other hematologic malignancies due to fatigue, pain, and trans
166 and are often activated in solid tumors and hematologic malignancies due to intratumoral hypoxia and
167 entially curative treatment for a variety of hematologic malignancies due to the well-recognized graf
169 monstrated tremendous success in eradicating hematologic malignancies (e.g., CD19 CARs in leukemias).
171 ical scenarios of HCV-infected patients with hematologic malignancies, focusing on diagnosis, clinica
172 alyzed cost-effectiveness studies related to hematologic malignancies from the Tufts Medical Center C
173 nt of chronic HCV infection in patients with hematologic malignancies has evolved rapidly as safe and
175 inical trials in patients with mIDH advanced hematologic malignancies have demonstrated compelling cl
176 CONCLUSION Critically ill patients with hematologic malignancies have good survival, disease con
177 oproliferative neoplasms (MPNs) and in other hematologic malignancies highlighted the role of JAK2 in
178 ated with increased MCC incidence, including hematologic malignancies, HIV/AIDS, and immunosuppressiv
180 ts with either solid tumor malignancy (STM); hematologic malignancy (HM); human immunodeficiency viru
181 sociated with poor outcomes in patients with hematologic malignancies (HMs) and hematopoietic cell tr
182 iral infections still occur in patients with hematologic malignancies (HMs) and in recipients of hema
184 age, gender, admission type, neoplasm, AIDS, hematologic malignancy, immunologic insufficiency, mecha
185 analyzed 2646 transplantations performed for hematologic malignancies in 28 German transplant centers
186 f a panel of 28 genes recurrently mutated in hematologic malignancies in a cohort of patients with MF
189 e limited success with free antisense ONs in hematologic malignancies in recent clinical trials has b
191 suppressor that prevents the development of hematologic malignancy in the setting of alkylation dama
192 ominant transmission of thrombocytopenia and hematologic malignancy in three unrelated kindreds, defi
193 ated with worse survival in most subtypes of hematologic malignancies, in a dose-response fashion.
194 T-cell therapeutics in patients with B-cell hematologic malignancies, in light of differences in CAR
196 or suppressor that is often mutated in human hematologic malignancies including AML and adds to their
197 ibits potent antileukemic effects on several hematologic malignancies including chronic myeloid leuke
198 e shown significant promise in patients with hematologic malignancies, including (i) conventional mon
199 icated elevated Apaf-1 expression in several hematologic malignancies, including acute lymphoblastic
200 currently also under investigation in other hematologic malignancies, including acute lymphoblastic
201 ] are recurring cytogenetic abnormalities in hematologic malignancies, including acute myeloid leukem
202 ve uncovered a spectrum of mutations in many hematologic malignancies, including acute myeloid leukem
203 TLR9 is also expressed by several human hematologic malignancies, including B-cell lymphoma, mul
204 l dysfunctions have been reported in various hematologic malignancies, including chronic lymphocytic
205 Managing these patients with hereditary hematologic malignancies, including familial leukemia, r
207 ation of variants associated with hereditary hematologic malignancies, including the importance of an
208 of 3 approaches to molecular diagnostics in hematologic malignancies: indication-specific single gen
209 reased probabilities of dying as a result of hematologic malignancies, infections, and, in young pati
210 at of matched controls, primarily because of hematologic malignancy, infections, and vascular events
211 Diagnosis of an inherited predisposition to hematologic malignancy informs choice of therapy, risk o
216 SCT) is potentially curative for a number of hematologic malignancies, its use is limited by the deve
217 the clinical outcome of patients, including hematologic malignancies (leukemia and lymphoma), solid
218 data suggest that innovative treatments for hematologic malignancies may provide reasonable value fo
222 5 individuals with breast cancer (n=51) or a hematologic malignancy (n=14), we measured left ventricu
224 macologic thromboprophylaxis than those with hematologic malignancies (odds ratio [OR], 2.34; 95% CI,
225 factors were associated with ICU admission: hematologic malignancy (odds ratio, 1.51; 95% CI, 1.26-1
226 Multiple myeloma (MM) is an age-related hematologic malignancy of clonal bone marrow plasma cell
227 n HSCs invariably lead to the development of hematologic malignancies or bone marrow failure syndrome
228 The study included 38,060 patients with hematologic malignancies or disorders who underwent firs
229 ddress platelet transfusion in patients with hematologic malignancies or solid tumors or in those who
230 hom 317 (84.7%) were receiving treatment for hematologic malignancies or solid tumors, at 28 intensiv
231 underlying respiratory diseases (and without hematologic malignancy or previous solid organ transplan
232 disease due to EV-D68 in adult patients with hematologic malignancy or undergoing hematopoietic cell
233 y produced TPO (a microenvironment factor in hematologic malignancies) or c-MPL-targeted pharmacologi
234 PDCN) is an aggressive and largely incurable hematologic malignancy originating from plasmacytoid den
235 ntified in families with additional types of hematologic malignancies, our group screened two cohorts
238 h free peptide alpha-amines in the plasma of hematologic malignancy patients soon after beginning tre
239 entical BMT with PTCy, 372 consecutive adult hematologic malignancy patients who underwent this proce
240 undergoing T-cell-replete first alloHCT for hematologic malignancies performed contemporaneously at
242 ome inhibitors, and to demonstrate that many hematologic malignancies predominantly express immunopro
244 2 regulates MYC, which has a pivotal role in hematologic malignancies, providing a preclinical proof
251 investigate the risk and outcomes of second hematologic malignancies (SHMs) in a population-based co
252 nts are those who have been diagnosed with a hematologic malignancy, solid organ tumor, or who have o
254 e (PI3K) signaling, is frequently mutated in hematologic malignancies such as bone marrow failure and
255 teasome inhibitor bortezomib is effective in hematologic malignancies such as multiple myeloma but ha
257 rived acute myeloid leukemia (AML) and other hematologic malignancies such as myelofibrosis (MF) in m
258 The recognition that patients with inherited hematologic malignancy syndromes may present without cla
259 yndrome was not more frequently related with hematologic malignancies than classic neutrophilic Sweet
260 syndrome is more frequently associated with hematologic malignancies than classic Sweet syndrome.
261 R) T cells can produce durable remissions in hematologic malignancies that are not responsive to stan
262 agent in the treatment of several solid and hematologic malignancies that exerts strong immune- and
264 te myeloid leukemia (AML) is a heterogeneous hematologic malignancy that originates from leukemia-ini
265 c leukemia (T-ALL) is a highly proliferative hematologic malignancy that results from the transformat
266 suggest that in contrast to the findings in hematologic malignancies, the adaptor protein LNK acts a
267 onses in patients with advanced melanoma and hematologic malignancy, the success against solid cancer
268 s at a single institution undergoing HCT for hematologic malignancy, the use of inpatient palliative
269 s allowed a potentially curative therapy for hematologic malignancies to be offered to an expanded pa
270 D19 CARs relate to greater susceptibility of hematologic malignancies to CAR therapies, or superior f
271 ndition, such as severe infections, solid or hematologic malignancies, trauma, or obstetric calamitie
273 nsplantation (HCT) in patients with advanced hematologic malignancies unable to tolerate high-intensi
274 (VitD) deficiency is common in patients with hematologic malignancies undergoing allogeneic transplan
275 domized clinical trial among 160 adults with hematologic malignancies undergoing autologous/allogenei
276 chromatin-modifying enzymes are involved in hematologic malignancies, underscoring the importance of
278 erved during this same period in an adjacent hematologic malignancy unit, which followed the same inf
279 a platform for the adoptive immunotherapy of hematologic malignancies using donor lymphocyte infusion
280 although mortality from prostate cancer and hematologic malignancies was noted in the American Cance
281 rmline mutations in children and adults with hematologic malignancies was previously underappreciated
283 years; range, 21 to 65 years) with high-risk hematologic malignancies were enrolled at three centers.
285 high-risk neutropenic patients (FhrNPs) with hematologic malignancies were randomly assigned to recei
286 residents (n = 1,792; 52% allogeneic and 90% hematologic malignancies) were frequency matched by demo
288 st 3 days of life were more likely to have a hematologic malignancy, were more likely to be male and
289 , but much less immunogenic in patients with hematologic malignancies where the immune system is supp
290 International Consensus Meeting of Prenatal Hematologic Malignancies, which took place in Leuven, Be
291 eukemia (AML) is a genetically heterogeneous hematologic malignancy, which is initiated and driven by
292 thods We randomly assigned 160 patients with hematologic malignancies who underwent autologous or all
294 nts and Methods A total of 681 patients with hematologic malignancy who underwent transplantation in
299 lenalidomide) are limited in application to hematologic malignancies, with only marginal efficacy in
300 the highest familial predispositions of all hematologic malignancies, yet the genetic basis for thes
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。